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Abstract
Background: The population longitudinal study named “The Conselice Study” has been the focus of the present
investigation. 65 years old or older participants of this population study on brain aging were followed up for 5
years: 937 subjects completed the follow-up. Relationships of 46 genetic, phenotypic, clinical and nutritional factors
on incident cognitive decline and incident dementia cases were investigated.
Results: A new statistical approach, called the Auto Contractive Map (AutoCM) was applied to find relationship
between variables and a possible hierarchy in the relevance of each variable with incident dementia. This method,
based on an artificial adaptive system, was able to define the association strength of each variable with all the
others. Moreover, few variables resulted to be aggregation points in the variable connectivity map related to
cognitive decline and dementia. Gene variants and cognate phenotypic variables showed differential degrees of
relevance to brain aging and dementia. A risk map for age associated cognitive decline and dementia has been
constructed and will be presented and discussed.
Conclusion: This map of variables may be use to identify subjects with increased risk of developing cognitive
decline end/or dementia and provide pivotal information for early intervention protocols for prevention of
dementia.
Background
Inflammatory responses during ageing
A dramatic increase in mean life span and life expec-
tancy, coupled with a significant reduction in early mor-
tality, has lead to a substantial increment in the number
of elderly population in contemporary societies. This
demographic picture parallels the merging of a new epi-
demic characterized by chronic age related diseases.
Most age related diseases have complex aetiology and
pathogenesis. Clinical diagnosis and therapy of these dis-
eases imply multidisciplinary medical approaches and
their cost is progressively increasing.
The immune system is often implicated, with a vari-
able degree of importance, in almost all age related dis-
eases or associated with their clinical complications.
Both innate and clonotypic immune system are usually
involved in the pathogenesis of these chronic diseases.
However, inflammatory responses appear to be the pre-
valent trigger mechanism driving tissue damages asso-
ciated with different age-related [1].
Chronic inflammation is involved in the pathogenesis
of all age-related diseases: Alzheimer’sd i s e a s e ,a t h e r o -
sclerosis, diabetes, autoimmune diseases, sarcopenia and
cancer have an important inflammatory component.
Furthermore, increased levels of circulating inflamma-
tory mediators may result from a constant, low-grade
activation of cytokine producing cells or a dysregulated
cytokine response following stimulation [2].
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sure to precedent infections which have become latent
infections and are able to induce chronic inflammation.
A continuous chronic activation of immune responses
then may lead and to increased risk of heart attack,
stroke, and cancer. For example, the risk of heart attack
and stroke is correlated with serum levels of inflamma-
tory proteins such as CRP. Within individuals, CRP
levels are also correlated to the number of seropositiv-
ities to common pathogens, indicating a history of infec-
tions (FINCH).
Low-grade increment of circulating TNF-a, IL-6, solu-
ble IL-2 receptor (sIL-2R), and C reactive protein (CRP)
and decreased levels of albumin and cholesterol, which
also are indicators of inflammatory state, are strong pre-
dictors of all-cause mortality risk in longitudinal studies
of several elderly cohorts. The effects of inflammatory
mediators are independent of pre-existing morbidity and
of other traditional risk factors for death (smoking,
blood pressure, physical exercise, total cholesterol,
co-morbidity, body mass index, and intake of anti-
inflammatory drugs) in survival analyses suggesting that
cytokines trigger/exaggerate pathological processes or
act as very sensitive markers of subclinical disorders in
elderly populations [2-8].
Therefore, innate immunity appears to play a pivotal
role in several age related diseases and therapeutic con-
trol of chronic inflammation is becoming an emerging
topics of modern gerontology and clinical geriatrics.
Brain degenerative diseases: Alzheimer’s disease
Alzheimer’s disease (AD) is a heterogeneous and pro-
gressive neurodegenerative disease that in Western
societies accounts for the majority of clinical senile
dementia and by 2050 the number of patients with AD
is expected to rise from 4.6 to 16 millions cases in the
USA [9]; worldwide statistical projections predict more
that 45 million of AD patients within the above year.
Neuropathological hallmarks of AD are extracellular
amyloid deposits (neuritic plaques) and intracellular
deposition of degenerate filaments (neurofibrillary tan-
gles) [10]. Major clinical manifestations of the disease
are memory loss and cognitive impairment [11].
Inflammation clearly occurs in pathologically vulner-
able regions of the AD brain, and it does so with the
full complexity of local peripheral inflammatory
responses. In the periphery, degenerating tissue and the
deposition of highly insoluble abnormal materials are
classical stimulants of inflammation. Likewise, in the AD
brain damaged neurons and neurites and highly insolu-
ble Ab42 peptide deposits and neurofibrillary tangles
provide obvious stimuli for inflammation. Senile plaques
in AD brains are associated with reactive astrocytes and
activated microglial cells and cytokines and acute phase
proteins are overexpressed in microglia and astrocytes
surrounding neuropathological lesions in AD brains.
Inflammatory factors, such as cytokines, chemokines,
complement components and acute phase proteins co-
localize as secondary components in neuritic or senile
plaques or are over-produced in AD brains, and acti-
vated microglia surround senile plaques and areas of
neurodegeneration [12,13]. There is accumulating evi-
dence that Ab peptide may promote or exacerbate
inflammation by inducing glial cells to release immune
mediators. Moreover, microglial and astroglial cells sur-
rounding mature plaques in AD brains have been found
to express activation markers. Enriched populations of
human microglial cells isolated from mixed cell cultures
prepared from embryonic human telencephalon tissues
are able to express constitutively mRNA transcripts for
cytokines and chemokines and treatment with pro-
inflammatory stimuli as lipopolysaccharide or Ab pep-
tide led to increased expression of mRNA levels of these
inflammatory molecules [14].
The role of inflammation is further emphasized by a
number of clinical studies demonstrating that the long-
term use of non-steroidal anti-inflammatory drugs may
protect against AD. There are now a lot of published
observational studies demonstrating that people who are
known to be taking anti-inflammatory drugs consider-
ably reduce their odds of developing AD and population
studies have confirmed this negative association [15].
However, alternative hypothesises have been proposed.
In particular, this effect has been suggested largely due
to these drugs ability to inhibit angiogenesis. In fact, the
brain endothelium secretes the precursor substrate for
the beta-amyloid plaque and a neurotoxic peptide that
selectively kills cortical neurons. So, antiangiogenic
drugs targeting the abnormal brain endothelial cell
might be able to prevent and treat this disease [16].
The long-term prospective association between
dementia and the well knowni n f l a m m a t i o nm a r k e r
high-sensitivity C-reactive protein was evaluated in a
cohort of Japanese American men who were seen in the
second examination of the Honolulu Heart Program
(1968-1970) and subsequently were re-examined 25
years later for dementia in the Honolulu-Asia Aging
Study (1991-1996). In a random subsample of 1,050
Honolulu-Asia Aging Study cases and noncases, high-
sensitivity C-reactive protein concentrations were mea-
sured from serum taken at the second examination;
dementia was assessed in a clinical examination that
included neuroimaging and neuropsychological testing
and was evaluated using international criteria. Com-
pared with men in the lowest quartile (<0.34mg/L) of
high-sensitivity C-reactive protein, men in the upper
three quartiles had a 3-fold significantly increased risk
for all dementias combined, Alzheimer’sd i s e a s e ,a n d
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inflammatory markers may reflect not only peripheral
disease, but also cerebral disease mechanisms related to
dementia, and that these processes are measurable long
before clinical symptoms appear [17].
On the other hand, several other investigations have
shown increased blood levels of some cytokines, such as
IL-1b and IL-6, and acute phase proteins (a-1-antichymo-
trypsin, ACT) in patients with clinical AD [18-21]. There-
fore, altered immune responses in the brain and the
peripheral blood appeared to be associated with the dis-
ease. Finally, plasma levels of ACT also correlated with the
degree of cognitive impairment in AD patients form a
case-control study [96] suggesting that peripheral markers
of inflammation or impaired immune responses could be
used for monitoring the progression of the disease.
Moreover, elevated levels of IL-6 in both brain homo-
genates and peripheral blood from AD patients have
been reported [22]. These findings suggested that an
important, but still largely unknown, interplay between
brain and peripheral immune responses existed in the
diseases.
In conclusion, the brain lesions associated with AD,
which are referred to as neurofibrillary tangles and senile
plaques, are characterized by the presence of a broad
spectrum of inflammatory mediators, produced by resi-
dent brain cells, including neurons. Although secondary
to the fundamental pathology caused by the presence of
tangles and plaques, there is strong evidence that inflam-
mation exacerbates the neuronal loss. Accordingly, sev-
eral reports have appeared indicating that the risk of AD
is substantially influenced by several polymorphisms in
the promoter region, and other untranslated regions, of
genes encoding inflammatory mediators. Alleles that
favour increased expression of the inflammatory media-
tors or alleles that favour decreased expression of anti-
inflammatory mediators are more frequent in patients
with AD than in controls. The polymorphisms are fairly
c o m m o ni nt h eg e n e r a lp o p u l a t i o n ,s ot h e r ei sas t r o n g
likelihood that any given individual will inherit one or
more of the high-risk alleles [21].
Results
A summary of data derivation from the “Conselice”
investigation at the beginning of the study and after the
five year follow up is reported in Table 1.
A list of variable investigated and their functional
definition used in this study is reported in Tables 2
and 3.
The connectivity map related to 42 variables from
t h eC o n s e l i c es t u d yd a t ab a s ef o c u s e du p o nt h eA D ,
VD and CIND prevalent cases during the follow up
interval is shown in Figure 1. The map depicts the
most relevant associations present in the data base.
The figures on the connections lines are proportional
to the strength of connections. Chronological age was
the closest variable to prevalent AD. However, several
major biological hubs were identified: 1) low blood
cholesterol, 2) high BMI index, 3) low blood HDL, 4)
low blood folate.
Different genotypic, phenotypic, clinical, pharmacolo-
gical or habit variables converged to these diverse hubs
or cluster of connectivity. Low blood cholesterol levels
was the first hub directly linked with age. Elevated IL-6
blood levels and ACT geneotype appeared to influence
low cholesterol levels. The second hub was represented
by high BMI index; several other variables were con-
nected on high BMI. Increased blood cholesterol, APOE
4 allele, increased blood hcy, increased ACT and
V i t B 1 2 ,a n dt h em u t a t ea l l e l eo fH M G C Rg e n e .L o w
blood HDL was the third hub and several variable were
linked to this hub such as, male gender, increased blood
CRP levels, the mutated allele of IL-1 beta gene. The
fourth hub was low blood folate linked to APOE 3 and
2 alleles and the mutated ACT allele.
Third and fourth hubs in the connectivity map were
shared by prevalent CIND and VD cases. Low age was
directly connected with the CIND clinical state.
Whereas, increased blood ACT levels were directly
linked with prevalent VD.
Cognitive healthy status at the end of the follow up
was on the other extremity of the connectivity map; far
away from CIND, VD and on the opposite site of AD.




1 Final population Prevalent AD Cognitively NC
2 AD free
N= 1353 n = 337 n = 1016 n = 60 n = 19 n = 937
Followup2003/2004
Reassessed population Non reassessed
3 Final population Incident ADdementia Cognitively NC non classified AD free cohort
N = 937 n = 133 n = 804 n = 109 n = 4 n = 695
1 Refusals n = 271; Deceased n = 59; Not found n = 7.
2 NC = non classified.
3 Refusals n =74; Deceased n = 28; Not Found n = 31.
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AD is a complex and multi-factorial disease, therefore, it
is unlikely that a single biomarker may be determinant
in the diagnosis or monitoring the progression of the
disease.
The statistical analysis applied to elaborate biological
and clinical data was a new enter in the field of biology
and medicine. In fact, most common algorithms used in
medicine are limited by the following limitations: 1) the
analyses usually do not preserve the geometrical struc-
ture between variables when non linear relationships
among variables are not evident. 2) another factor of
uncertainty is how to establish precise associations
between variables without predefined contiguity.
Here we used a new paradigm aimed to map variables
and search for connectivity. In this analysis non linear
association were preserved, explicit connection schemes
were investigated and the complexity of dynamic inter-
actions were preserved. The mathematics and philoso-
phy of this analysis has been described in detail
elsewhere [23]. Some application of similar kind of this
analysis has already been focused to AD investigations
with interesting findings [24].
Findings described here generated a connectivity map
among variables and illustrated a rational path of biolo-
gical variables leading to prevalent dementia.
Data presented here suggest that age, low cholesterol,
high BMI, low HDL and low folate are major variable
associated with the risk of AD, VD and CIND. CIND, as
expected, were associated with a lower age at onset.
Our findings showed four major connecting nodes
from the Conselice data base; these hubs linked appar-
ently different factors to cognitive impairment and
dementia via cholesterol, cholesterol gene dependent
pathway, BMI and age. A new association among differ-
ent immunological factors and lipid metabolism with
incident dementia has also emerged.
In conclusion the connectivity map presented here on
prevalent dementia extents previous observations from
case/control investigations and population investigations
and confirm that some immune factors indeed play a
role in the pathogenesis of age-associated dementia by
modifying metabolic and lipid variables and also show a
new link between immunity, cholesterol metabolism and
age related cognitive deterioration.
Material and methods
Data base generation
Data were collected from the elderly (65 year old or
older) living in Conselice county in Northern Italy. Par-
ticipants were interviewed, medically examined and cog-
nitively evaluated in 1999. A blood sample from each
subject was taken and each participant was given a com-
puterized scan radiogram of the brain. After five years
subjects underwent medical and cognitive re-evaluation.
937 elderly completed the follow up. A detailed descrip-
tion of the clinical protocol and the assessed variable
has been already described elsewhere [25,26].
Diagnosis of dementia was performed according cri-
teria of DSM-IV (1994). Clinical AD was defined using
the NINCDS-ADRDA criteria [27]. Vascular dementia
(VD) was diagnosed using NINDS-AIREN criteria [28].
Diagnosis of CIND was performed according methods
already described [29].
Statistical analysis
Conselice data base has the aim of increasing our under-
standing of the pathogenetic pathway leading to cognitive
decline and dementia. This goal has been achieved
through a new mathematical approach able to point out
the relative relevance of each variable in representing
major biological hub or aggregation point. This new para-
digm of variables processing aims to create a semantic
connectivity map in which: a) non linear associations are
preserved, b) there are explicit connections schemes,
c) the complex dynamics of adaptive interactions is cap-
tured. This method is based on an artificial adaptive
Table 2 Genetic variables used in the connectivity map
Genetic variable (gene polymorphism)
gene SNP Allele mutated
ACT rs 1884082 T
APOE variation ε 2,3,4 ε 4
HMGCR rs3761740 A
IL-1 beta rs16944 T
IL-6 rs1800795 C
Table 3 Phenotypic and clinical variables used in the
connectivity map
Variable level
high ACT > 400 ug/ml
high cholesterol > 200 mg/dl
high CRP > 0.3 mg/ml
high HDL > 65 mg/dl
low HDL < 40 mg/dl
high IL-6 > 5 pg/ml
high TNFa > 20 pg/ml
high triglicerids > 175 mg/dl
high Hcy > 17 umol/l
high folate > 5.3 mg/dl
high TSH >0,4 mU/L
high vitB12 > 341 pg/ml
high BMI > 28
Hypertension > 140 mm hg
type II diabetes positive
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each variable with all the others in any dataset, named the
Auto Contractive Map (AutoCM). The architecture and
the mathematic of AutoCM was invented, tested and
implemented in C language, as described elsewhere [24].
T h ep h i l o s o p h yb e h i n dt h i sa p p r o a c hi st op i c ku pa f f i -
nities among variables related to their dynamical interac-
tion rather than to their simple contingent spatial position.
This approach is suggested more suitable to describe a
context typical of living systems in which there is a contin-
uous complex change in the variables values among time.
After the training phase, the weights matrix of the
AutoCM represents the warped landscape of the dataset.
We apply a simple filter (minimum spanning tree by Krus-
kal) to the weights matrix of AutoCM system to show the
map of main connections between and among variables
and the principal hubs of the system.
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